Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Pliant Therapeutics and MediWound, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pliant Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| MediWound | 1 | 1 | 4 | 0 | 2.50 |
Pliant Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 270.51%. MediWound has a consensus price target of $33.00, suggesting a potential upside of 131.58%. Given Pliant Therapeutics’ higher possible upside, research analysts plainly believe Pliant Therapeutics is more favorable than MediWound.
Volatility & Risk
Pliant Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500.
Earnings and Valuation
This table compares Pliant Therapeutics and MediWound”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pliant Therapeutics | N/A | N/A | -$149.34 million | ($1.49) | -0.54 |
| MediWound | $16.96 million | 10.93 | -$23.88 million | ($1.80) | -7.92 |
MediWound has higher revenue and earnings than Pliant Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Pliant Therapeutics and MediWound’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pliant Therapeutics | N/A | -52.17% | -40.46% |
| MediWound | -170.10% | -47.24% | -24.27% |
Institutional and Insider Ownership
97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 8.7% of Pliant Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
MediWound beats Pliant Therapeutics on 7 of the 13 factors compared between the two stocks.
About Pliant Therapeutics
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
